SAS ROTA TEST
K990842 · Sa Scientific, Inc. · LIQ · Aug 9, 1999 · Microbiology
Device Facts
| Record ID | K990842 |
| Device Name | SAS ROTA TEST |
| Applicant | Sa Scientific, Inc. |
| Product Code | LIQ · Microbiology |
| Decision Date | Aug 9, 1999 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 866.3405 |
| Device Class | Class 1 |
Intended Use
The SASTM Rota Test is a rapid, membrane-based immunogold assay for the qualitative detection of Rotavirus antigens in feces as an aid in the diagnosis of acute gastroenteritis caused by rotavirus infection. This test is for professional use only.
Device Story
SAS™ Rota Test is a rapid, membrane-based immunogold assay; detects Rotavirus antigens in human fecal samples. Used in clinical laboratory settings by professional personnel. Principle of operation involves immunochromatographic detection of viral antigens in stool specimens. Provides qualitative results to aid in diagnosing acute gastroenteritis. Benefits include rapid identification of rotavirus infection, facilitating timely clinical management of gastroenteritis.
Clinical Evidence
No clinical data provided in the document; bench testing only.
Technological Characteristics
Membrane-based immunogold assay; qualitative lateral flow format; professional use diagnostic test.
Indications for Use
Indicated for professional use in the qualitative detection of Rotavirus antigens in human fecal specimens to aid in the diagnosis of acute gastroenteritis caused by rotavirus infection.
Regulatory Classification
Identification
Poliovirus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to poliovirus in serum. Additionally, some of these reagents consist of poliovirus antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identify polioviruses from clinical specimens or from tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of poliomyelitis (polio) and provides epidemiological information on this disease. Poliomyelitis is an acute infectious disease which in its serious form affects the central nervous system resulting in atrophy (wasting away) of groups of muscles, ending in contraction and permanent deformity.
Related Devices
- K964424 — ROTAVIRUS EIA · Trinity Biotech, Inc. · Aug 8, 1997
- K971585 — IMMUNOCARD STAT! ROTAVIRUS · Meridian Diagnostics, Inc. · Aug 20, 1997
- K965092 — VIDAS ROTAVIRUS ASSAY · Biomerieux Vitek, Inc. · May 5, 1997
- K972895 — VIDAS ROTAVIRUS (RTV) ASSAY · Biomerieux Vitek, Inc. · Oct 3, 1997
- DEN110001 — RIDASCREEN NOROVIRUS 3RD GENERATION EIA · R-Biopharm AG · Feb 23, 2011
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles an abstract human figure or a caduceus, with three curved lines representing the body and a wavy line at the bottom.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
AUG - 9 1999
Mr. Josh Wessling Regulatory Affairs SA Scientific, Inc. 4919 Golden Quail San Antonio, Texas 78240
K990842 Re: Trade Name: SAS™ Rota Test Regulatory Class: I Product Code: LIQ Dated: June 18, 1999 Received: June 21, 1999
Dear Mr. Wessling:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
## Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours.
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## INDICATIONS FOR USE
SA Scientific, Inc. Applicant: 4919 Golden Quail San Antonio, TX 78240 Ph: (210) 699-8800 Fax: (210) 699-6545
Establishment Reg. No.: 1645225
510(k) Number: _______________________________________________________________________________________________________________________________________________________________
Device Name: SAS™ Rota Test
The SASTM Rota Test is a rapid, membrane-based immunogold Indication For Use: assay for the qualitative detection of Rotavirus antigens in feces as an aid in the diagnosis of acute gastroenteritis caused by rotavirus infection. This test is for professional use only.
(Please do not write below this line)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Per 21 CFR 801.109)
Woody Debris
ahorator 510(k) Number
Prescription Use X
Or
Over-the-Counter